Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress

Gethin R Ellis, Angus K Nightingale, Daniel J Blackman, Richard A Anderson, Catherine Mumford, Graham Timmins, Derek Lang, Simon K Jackson, Michael D Penney, Malcolm J Lewis, Michael P Frenneaux, Jayne Morris-Thurgood

Research output: Contribution to journalArticle (Academic Journal)peer-review

12 Citations (Scopus)

Abstract

Angiotensin II exerts a number of harmful effects in patients with chronic heart failure (CHF) and, through an increase in oxidative stress, is thought to be critical in the development of endothelial dysfunction. Angiotensin II may be elevated in CHF despite treatment with angiotensin converting enzyme (ACE) inhibitors, producing a rationale for adjunctive angiotensin receptor blockade. We investigated whether the addition of angiotensin antagonism to ACE inhibition would reduce oxidative stress and improve endothelial function and exercise tolerance in patients with chronic heart failure.
Original languageEnglish
Pages (from-to)193-9
Number of pages7
JournalEuropean Journal of Heart Failure
Volume4
Issue number2
Publication statusPublished - 2002

Fingerprint Dive into the research topics of 'Addition of candesartan to angiotensin converting enzyme inhibitor therapy in patients with chronic heart failure does not reduce levels of oxidative stress'. Together they form a unique fingerprint.

Cite this